| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 1g |
|
||
| Other Sizes |
| ln Vitro |
SB-405483 (2.5-25 μM) showed a binding potency of 25 ± 0.9 μM to the recombinant human CRBN/DDB1 complex and exhibited a high synergistic effect with the lenalidomide-Alexa647 probe [1]. SB-405483 (25 μM) enhanced the binding of various ortho-CRBN ligands to the recombinant human CRBN/DDB1 complex, with its IC50 value decreasing by 8.96 to 43.7 times, but had no effect on the binding of mecelidomide [1]. SB-405483 (0.1-25 μM; 1 h) stabilized endogenous CRBN in MM.1S cells in a dose-dependent manner, with enhanced stabilizing effect when co-treated with lenalidomide [1]. SB-405483 (0.1–10 μM) inhibited autoubiquitination of endogenous Flag-labeled CRBN in HEK293T cells in a dose-dependent manner [1]. SB-405483 (10 μM; 0.5–24 h) enhanced DEG-47-mediated degradation of endogenous CK1α in MOLM-13 cells [1]. SB-405483 (10 μM; 24 h) enhanced DEG-47-mediated degradation of Wee1 in A2780 Wee1-HiBiT cells and MOLM-13 cells [1]. SB-405483 (10 μM; 24 h) inhibited DEG-47-mediated degradation of IKZF1/3(ZF2)-GFP and IKZF2(ZF2)-GFP in HEK293T reporter cells for 24 hours [1]. SB-405483 (10 μM; 24 h) slightly enhanced DEG-47-mediated degradation of SALL4(ZF1,2)-GFP in U937 Cas9 cells [1].
|
|---|---|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: Human acute myeloid leukemia MOLM-13 cells Tested Concentrations: 10 μM Incubation Duration: 0.5, 1, 2, 4, 6, 24 hours Experimental Results: In the GFP-CK1α reporter gene assay, the DC50 value of DEG-47 decreased from 21 nM to 5 nM after 24 hours. CK1α expression was reduced. |
| References |
| Molecular Formula |
C20H16N4O3
|
|---|---|
| Molecular Weight |
360.37
|
| Appearance |
White to light yellow solid
|
| SMILES |
O=C(NC1=CC=C(C#N)C=C1O)NC2=NC=CC=C2OCC3=CC=CC=C3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封且受保护的环境中（例如氮气下），避免暴露在潮湿环境中。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~69.37 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7749 mL | 13.8746 mL | 27.7493 mL | |
| 5 mM | 0.5550 mL | 2.7749 mL | 5.5499 mL | |
| 10 mM | 0.2775 mL | 1.3875 mL | 2.7749 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
